Terumo Aortic today announced that the US Centers for Medicare and Medicaid Services (CMS) has granted approval of a new technology add-on payment (NTAP) for Terumo Aortic’s Thoraflex Hybrid device under the inpatient prospective payment system (IPPS).
Cardionovum has announced the enrolment of the first patient in the international Hyper II clinical study designed to evaluate the safety and efficacy at 12 months of the hybrid treatment approach combining the Restore drug-coated balloon (DCB) with new a generation drug-eluting stent (DES) in long diffuse coronary artery disease (CAD).
Abbott has announced the release of late-breaking showing that its HeartMate 3 heart pump extends survival of advanced heart failure patients by at least five years.
The timing of dosing of antihypertensive medication—whether it is taken in the morning or in the evening—does not have a bearing on cardiovascular outcomes, randomised trial results presented during a hot line session at the European Society of Cardiology (ESC) annual congress (26–29 August, Barcelona, Spain) indicate.
The American Heart Association (Association) and the Cardiovascular Research Foundation (CRF) have announced a new alliance to produce joint education programmes, beginning with the organisations’ annual scientific meetings this autumn.
Projected rates of cardiovascular risk factors and disease will increase significantly in the USA by 2060, a study published in the Journal of the American College of Cardiology(JACC) has claimed.
Cardiac surgeons from North America, Europe and Latin America are among the signatories to a multidisciplinary group seeking to address what it describes as a “widening gap” between evidence and guideline recommendations in cardiovascular medicine.
A project to develop genetic therapies to effectively cure cardiomyopathy has been announced as the winner of the British Heart Foundation’s Big Beat Challenge, a £30 million innovation projecttargeting unmet needs in heart disease.
Incentives for the enrolment of patients from socieconomically disadvantaged groups, as well as targets for racial and ethnic minority patients, may be a way to ensure that clinical trials of devices for structural heart disease are more representative of the wider population, attendees of The Structural Heart Summit (TVT 2022, 8–10 June, Chicago, USA) heard.
Cathbot—a joint venture between Robocath and MicroPort—has enrolled the last patient in its clinical study in China. This is the first step towards obtaining approval from China’s National Medical Products Administration (NMPA) for the commercialisation of R-One, the robotic percutaneous coronary intervention (PCI) platform, in the Chinese market.
Preventing coronary obstruction after transcatheter aortic valve implantation (TAVI) becomes increasingly important as the procedure moves into a lower-risk patient population. According to researchers in Europe and Israel, a new device may offer a simple solution to preventing this complication in TAVI patients.
Ancora Heart has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the Accucinch ventricular restoration system.
Performance diagnostique de l’interféron gamma dans l’identification de l’origine tuberculeuse des pleurésies exsudatives
A Mixed Phenotype of Airway Wall Thickening and Emphysema Is Associated with Dyspnea and Hospitalization for Chronic Obstructive Pulmonary Disease.
Radiological Approach to Asthma and COPD-The Role of Computed Tomography.
Significant annual cost savings found with UrgoStart in UK and Germany
Thrombolex announces 510(k) clearance of Bashir catheter systems for thromboembolic disorders
Phone: (028) 3981 2678
Mobile: 0903 839 878 - 0909 384 389